[email protected]

Login

Papers

Journal of Crohn's and Colitis, Volume 20, Issue 8, August 2026, jjag100, https://doi.org/10.1093/ecco-jcc/jjag100
Characterization of remission levels in patients with ulcerative colitis treated with 5-aminosalicylates

Acta Gastro-Enterologica Belgica. 2026;89(2):373-383. doi 10.51821/89.2.14962
Multi-stakeholder Delphi consensus on future care for inflammatory bowel disease in Belgium

Acta Gastro-Enterologica Belgica. 2026;89(2):148–157. doi 10.51821/89.2.14879
From theory to practice: a Belgian consensus on minimal monitoring strategies for patients with IBD treated with advanced therapies

Gastroenterology . 2026 Feb 24:S0016-5085(26)00146-0. doi: 10.1053/j.gastro.2026.01.042. Online ahead of print.
The effect of dose-intensification after secondary loss of response to ustekinumab in Crohn's disease: Results of the REScUE study

Journal of Crohn's and Colitis, jjad179, Epub: 02 November 2023
Early versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological Outcomes

Eur J Cancer . 2023 Jul;187:36-57. doi: 10.1016/j.ejca.2023.03.025. Epub 2023 Mar 25.
Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus

Journal of Crohn's and Colitis, 27 September 2022, jjac145
What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Infammatory Bowel Disease? A Qualitative Patient Preference Study

Gastroenterology. 2022 Aug 5;S0016-5085(22)00828-9
Effect of 5-hydroxytryptophan on fatigue in quiescent inflammatory bowel disease: a randomized controlled trial

1
2
3
4
5
6
7
›